<DOC>
	<DOCNO>NCT02471404</DOCNO>
	<brief_summary>This study carry see dapagliflozin dapagliflozin plus saxagliptin addition metformin effective safe treat patient type 2 diabetes compare glimepiride ( sulphonylurea ) addition metformin treatment .</brief_summary>
	<brief_title>Efficacy Safety Dapagliflozin Dapagliflozin Plus Saxagliptin Combination With Metformin Type 2 Diabetes Patients Compared With Sulphonylurea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Main 1 . Is male female ≥18 &lt; 75 year old time inform consent . 2 . Has HbA1c ≥7.5 % ≤10.5 % base central laboratory result Visit 1 , individual need therapy escalation . 3 . Currently treat stable maximum tolarated dose ( MTD ) ( ≥1500 mg/day ) metformin therapy least 8 week prior Enrolment visit . 4 . Has BMI ≤45 kg/m2 Enrolment visit . 5 . Has Cpeptide laboratory value ≥1.0 ng/mL ( 0.33 nmol/L ; 333.3 pmol/L ) base central laboratory result Visit 1 . Main , 1 . Clinically diagnosed Type I diabetes , know diagnosis maturity onset diabetes young ( MODY ) , secondary diabetes mellitus know presence glutamate decarboxylase 65 ( GAD65 ) antibody . 2 . Patients , judgment Investigator , may risk dehydration volume depletion may affect patient 's safety and/or interpretation efficacy safety data . 3 . Clinically significant cardiovascular disease procedure within 3 month prior Enrolment expect require coronary revascularization procedure course study . 4 . Concomitant treatment loop diuretic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes Mellitus Type 2 ,</keyword>
	<keyword>metformin ,</keyword>
	<keyword>saxagliptin ,</keyword>
	<keyword>dapagliflozin ,</keyword>
	<keyword>glimepiride ,</keyword>
	<keyword>inadequate glycaemic control</keyword>
</DOC>